Uploaded May 2022 | Updated November 2026, 8 hours ago
INCLUSIVITY, DIVERSITY, AND EQUITY AWARD (IDEAWARD)
INTERLEUKIN-37 ENHANCES THE EFFECTIVENESS OF CAR T-CELL THERAPY
CURTIS HENRY, PHD; SUNIL RAIKAR, MD; SARWISH RAFIQ, PHD
A diverse team of researchers at Emory have developed IL-37-expressing CAR T-cells to treat B-cell acute lymphoblastic leukemia. These cells not only boost the function of aged T-cells, but also enhance the effectiveness of CAR T-cell therapy. Acute lymphoblastic leukemia (ALL) is a highly aggressive type of leukemia and requires very early treatment. Unfortunately, CAR T-cell therapy leads to unsustainable remissions in a majority of patients, and major toxicity due to cytokine release syndrome often occurs. More efficient therapies are highly important in order to increase CAR T-cell longevity and reduce toxicity. In addition to a diverse lab, Curtis Henry, PhD, also serves on the Inclusion, Diversity, Equity and Advancement (IDEA) committee within the Cancer Biology graduate program. This committee’s goal is to take a proactive stance in the creation of an academic environment that is inclusive, welcoming, and celebrates contributions of brilliant scientists from underrepresented groups.
More information: https://www.ott.emory.edu/about/annual-celebrations/index.html
INCLUSIVITY, DIVERSITY, AND EQUITY AWARD (IDEAWARD)
INTERLEUKIN-37 ENHANCES THE EFFECTIVENESS OF CAR T-CELL THERAPY
CURTIS HENRY, PHD; SUNIL RAIKAR, MD; SARWISH RAFIQ, PHD
A diverse team of researchers at Emory have developed IL-37-expressing CAR T-cells to treat B-cell acute lymphoblastic leukemia. These cells not only boost the function of aged T-cells, but also enhance the effectiveness of CAR T-cell therapy. Acute lymphoblastic leukemia (ALL) is a highly aggressive type of leukemia and requires very early treatment. Unfortunately, CAR T-cell therapy leads to unsustainable remissions in a majority of patients, and major toxicity due to cytokine release syndrome often occurs. More efficient therapies are highly important in order to increase CAR T-cell longevity and reduce toxicity. In addition to a diverse lab, Curtis Henry, PhD, also serves on the Inclusion, Diversity, Equity and Advancement (IDEA) committee within the Cancer Biology graduate program. This committee’s goal is to take a proactive stance in the creation of an academic environment that is inclusive, welcoming, and celebrates contributions of brilliant scientists from underrepresented groups.
More information: https://www.ott.emory.edu/about/annual-celebrations/index.html










